On 1 October 2019 the funded brand of lamotrigine changed from Lamictal, Arrow-Lamotrigine and Logem to Logem only.
Lamotrigine is used to treat epilepsy and some mental health conditions, such as bipolar disorder.
Exceptional circumstances applications
Total received: 2,037
Under assessment: 90
Declined or withdrawn: 14
Updated: 5 February 2020
Media releases and OIA responses
Media releases about lamotrigine brand change
- 15 November 2019 – PHARMAC to widen access to the exceptional circumstances process for lamotrigine
- 1 October 2019 – Lamotrigine brand change from today
Responses to Official Information Act requests about lamotrigine
- 24 December 2019 – Number of exceptional circumstances applications (Note: Latest information is on this page)
- 19 December 2019 – Advice around costs of lamotrigine brand change
- 18 December 2019 – Lamotrigine contingency plan activation
- 17 December 2019 – Lamotrigine NPPA change
- 18 November 2019 – Venlafaxine and lamotrigine NPPA data
- 6 November 2019 – Lamotrigine safety
Details of the decision process
- 11 April 2019 – Decision to move to one funded brand of lamotrigine (Logem)
- 7 February 2019 – Advice from the Joint Neurology and Mental Health PTAC subcommittee [PDF, 194 KB]
- 26 October 2018 – Update on proposal to move to one funded brand of lamotrigine (Logem)
- 22 August 2018 – Proposal to move to one funded brand of lamotrigine (Logem)
- 14 June 2018 – Request for proposals (RFP): Supply of lamotrigine chewable/dispersible tablets
PHARMAC is aware that deaths have been reported to the Centre for Adverse Reactions Monitoring (CARM) as potential adverse reactions to the brand change. There is currently no evidence linking the deaths to the brand change. We cannot comment further while the Chief Coroner investigates these deaths.
To reassure people taking lamotrigine, we widened our rules so more people could stay on their current brand of lamotrigine. We are continuing to monitor the situation.